A shift in how IoT is secured by default

Tern plc

The release of KeyScaler 2025 marks a transformational moment for organisations wrestling with sprawling IoT and OT device estates. Rather than accepting the traditional burden of manual certificate issuance, policy definition and certificate revocation across thousands or even millions of devices, KeyScaler 2025 introduces a fully automated, AI‑driven trust lifecycle.

Manual processes have long been the Achilles’ heel of large‑scale deployments, introducing delays, human error and security gaps. By embedding AI that continuously monitors device behaviour, identity attributes and compliance posture, KeyScaler 2025 is designed to detect anomalies and potential threats in real time, and to trigger remediation automatically.

The platform incorporates a ‘Policy Intelligence Engine’ that enforces zero‑trust principles dynamically, adapts permissions based on contextual threat data and ensures data exchanges remain encrypted and auditable. For industries such as manufacturing, healthcare, energy or logistics, these features offer critical assurances.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Search